AGM/EGMMay 6, 2026, 07:26 AM
NewAmsterdam Pharma Schedules 2026 AGM for June 2
AI Summary
NewAmsterdam Pharma Company N.V. announced its Annual General Meeting of Shareholders will be held on June 2, 2026, in Amsterdam. The agenda includes key corporate governance items such as the adoption of the 2025 Dutch statutory annual accounts and the discharge of directors from liability. Shareholders will also vote on the reappointment of two non-executive directors, the instruction and ratification of Deloitte Accountants B.V. as auditor for 2026, and the extension of the Board's authorization to issue shares and limit pre-emption rights. Additionally, approval for the 2026 Employee Stock Purchase Plan and an advisory vote on 2025 executive compensation are on the ballot.
Key Highlights
- Annual General Meeting scheduled for June 2, 2026, at 5:00 p.m. CEST in Amsterdam.
- Shareholders to vote on adopting the 2025 Dutch statutory annual accounts.
- Proposal to discharge directors from liability for duties performed in fiscal year 2025.
- Deloitte Accountants B.V. nominated and ratified as external auditor for fiscal year 2026.
- Reappointment of John W. Smither and Janneke van der Kamp as non-executive directors until 2030.
- Extension of Board authorization to issue ordinary shares and limit pre-emption rights.
- Approval sought for the NewAmsterdam Pharma Company N.V. 2026 Employee Stock Purchase Plan.
- Non-binding advisory vote on 2025 named executive officer compensation.
Price Impact
More from NAMS